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The aim of this study is to examine the effect of the instillation method on absorption 
of a drug from the liver and small intestinal serosal surface in rats.   We performed 
continuous microinstillation via an infusion pump and bolus instillation via a syringe.   
Phenol red as a model was absorbed after continuous microinstillation of 2.35 mg in 
235 µL for 5 min on the liver and small intestinal serosal surface in rats with a 
significantly higher AUC of the plasma concentration profile until 60 min, compared 
with that after bolus instillation.   A similar trend was observed after continuous 
microinstillation of 2.35 mg in 117.5 µL for 2.5 min.   The calculated absorption rate 
constants Ka after continuous microinstillation of phenol red based on a 
two-compartment model with first-order absorption were higher than those after bolus 
instillation on the liver and small intestinal serosal surface at either instillation 
concentration.   Moreover, Ka was increased after continuous microinstillation of 
2.35 mg in 117.5 µL on either instillation site.   In the comparison between 
instillation sites, instillation of phenol red on the liver surface resulted in 1.2 to 2.3-fold 
higher Ka, compared to small intestinal serosal surface.   This tendency was marked 
after continuous microinstillation of 2.35 mg in 117.5 µL.   In conclusion, absorption 
could be enhanced by instilling a small amount of drug solution on the liver surface 
gradually and continuously, suggesting a promising approach for instillation 




The intraperitoneal (ip) administration method has been used for application of anticancer 
drugs that are difficult for oral administration.   For ip administration to liver cancer 
chemotherapy, the drug solution after ip administration is expected to distribute preferentially 
around the diseased region in the liver.   Although iv, hepatic arterial and portal 
administration have been attempted as targeted delivery methods (Anderson et al 1994), the 
administered drug tends to distribute through the entire liver.   We have previously shown 
that direct injection into an organ is not suitable for site-selective drug delivery to the liver 
with a high blood flow, since directly injected drugs are rapidly cleared from the injection site 
and enter the systemic circulation (Nishida et al 1994).   Therefore, it was suggested that 
instillation of a small amount of drug solution continuously should be effective to keep a high 
concentration of drug around the liver surface.   Recently, implantable infusion pumps have 
been developed for treatment of several diseases (Hepp 1994), and endoscopic and 
laparoscopic operation techniques have been markedly improved (Stellato 1992).   These 
advanced medical technologies should make possible the clinical use of continuous 
microinstillation of drugs on the liver surface and other regions in the peritoneal cavity. 
 After instillation of drug solution on the liver surface, drugs are believed to spread 
throughout the peritoneal cavity and to be diluted by serous fluid and ascites, leading to a 
reduction of drug accumulation around the instillation site.   Therefore, we examined the 
effect of the instillation method on the absorption characteristics from the liver surface and 
compared it with that after instillation on the small intestinal serosal surface in the peritoneal 
cavity.   In addition, we studied the influence of the instillation drug concentration and 
volume on the absorption rate.   In this study, we selected phenol red as a model drug, 
because its absorption mechanism from the liver surface in rats has been clarified (Nishida et 
al 1995a).   Phenol red, a hydrophilic dye (organic anion), has been clinically used as a renal 
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function test compound in humans, and is excreted into bile and urine as a free form or 
conjugative metabolite in rats (Hart & Schanker 1966).
4 
 
Materials and Methods 
Animal study 
All animal experiments in the present study conformed to the Guideline for Animal 
Experimentation in Nagasaki University.   Male Wistar rats (230-270 g), which were not 
starved, were anaesthetized with sodium pentobarbitone (50 mg kg-1 body weight, 
intramuscular injection), and an incision was made in the middle abdomen.   The left 
femoral artery and common bile duct were cannulated with a polyethylene tube.   Additional 
sodium pentobarbitone was administered as necessary during the experiment to maintain 
anaesthesia.   Phenol red (Nacalai Tesque, Inc., Kyoto, Japan) solution was prepared in 
isotonic phosphate buffer (pH 7.4) to yield a concentration of 10 or 20 mg mL-1, and 
administered as follows.   A schematic diagram of the instillation method is shown in Figure 
1. 
 
 Continuous microinstillation on the liver or small intestinal serosal surface:  The phenol 
red solution (20 mg mL-1 X 117.5 µL or 10 mg mL-1 X 235 µL) was instilled using a 
polyethylene tube fixed by a clamp on the surface of the left lateral liver lobe or distal small 
intestine with an infusion pump (flow rate 0.047 mL min-1) (Natsume, Tokyo, Japan) for 2.5 
and 5 min, respectively. 
 Bolus instillation on the liver or small intestinal serosal surface:  The phenol red 
solution (20 mg mL-1 X 117.5 µL or 10 mg mL-1 X 235 µL) was instilled momentarily on the 
surface of the left lateral lobe or distal small intestine using a syringe. 
 
 After instillation of phenol red solution, 200 µL blood was collected for 12 times at 2, 5, 
10, 15, 30, 60, 90, 120, 150, 180, 210 and 240 min from the heparinized cannula inserted into 
the femoral artery for 4 h.   Blood was centrifuged at 15,000 rev min-1 for 5 min.   Bile 
samples were collected at appropriate time intervals for 4 h.   At 4 h after instillation, the 
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solution remaining in the peritoneal cavity was withdrawn by washing with saline. 
 The concentration of free phenol red was determined spectrophotometrically at 560 nm 
after dilution with 1 M NaOH.   The total concentration of free phenol red and its 
conjugative metabolite (glucuronic acid conjugate) was measured in the same manner after 
the samples were subjected to acid hydrolysis (1 M HCl at 100°C for 30 min) (Hart & 
Schanker 1966).   The concentration of phenol red metabolite was estimated from the 
difference between these values.   The phenol red metabolite could not be detected in the 
plasma.
Pharmacokinetic analysis with a compartment model 
Compartment model analysis of the plasma concentration profile of phenol red after bolus 
instillation or continuous microinstillation on the liver or small intestinal serosal surface in 
rats was performed based on a two-compartment model with first-order absorption as follows 
by the nonlinear least-squares method (Yamaoka et al 1981).   The pharmacokinetic models 
are illustrated in Figures 2A and 2B. 
Bolus instillation: The equation for concentration of central compartment (C1) after bolus 































KDFC  (2) 
Hybrid parameters α and β are defined as α + β = K12 + K21 + Kel and α·β = K21·Kel.   Vc is 
the volume of the central compartment.   Kel is the first-order elimination rate constant from 
the central compartment.   K12 and K21 are the first-order transfer rate constants between the 
central and peripheral compartment.   Ka is the first-order absorption rate constant for 
absorption into the blood stream from the liver or small intestinal serosal surface.   D is the 
instilled dose, and F is the availability after instillation.   The result for i.v. administration of 
phenol red was reported previously (Nishida et al 1995a). 
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Continuous microinstillation: In continuous microinstillation, we first analyzed the plasma 
concentration profile after the end of instillation (t0) with a two-compartment model as shown 
in Figure 2B according to equation 3 by the nonlinear least-squares method (Yamaoka et al 
1981).   In equation 3, Xip(0) is the drug amount in intraperitoneal compartment at the end 
of instillation (t0).   C1(0) and C2(0) are concentrations of central and peripheral 
compartment at the end of instillation (t0), respectively.   After obtaining the 
pharmacokinetic parameters (Ka and F), the plasma concentration profile before the end of 
instillation (t < t0) was simulated according to equation 4.   In equation 4, K0 is the drug 
instillation rate. 
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Statistical analysis was performed by applying unpaired Student’s t-test.   P < 0.05 was 
considered to be statistically significant.   All values were expressed as the mean value ± 
standard error of at least four experiments. 
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Results and Discussion 
Effect of the instillation method on the absorption of phenol red from the liver 
and small intestinal serosal surface 
We performed continuous microinstillation via an infusion pump and bolus instillation via a 
syringe of 2.35 mg in 235 or 117.5 µL of phenol red solution on the liver and small intestinal 
serosal surface in rats.   The plasma concentration profiles of phenol red are shown in 
Figures 3A and 3B in a solution of 2.35 mg in 235 µL.   The plasma concentrations of 
phenol red after continuous microinstillation of 2.35 mg in 235 µL for 5 min on the liver and 
small intestinal serosal surface are higher in the first 60 min than those after bolus instillation.   
In addition, the maximum plasma concentration was increased by 1.5- or 1.3-fold after 
continuous microinstillation on the liver and small intestinal serosal surface, respectively, 
compared with bolus instillation (Figures 3A and 3B). 
 Figures 4A and 4B show similar findings for instillation of phenol red solution of 2.35 
mg in 117.5 µL.   A similar tendency of higher maximum concentration was observed in the 
plasma concentration profiles of phenol red after continuous microinstillation of 2.35 mg in 
117.5 µL for 2.5 min, compared with bolus instillation (Figures 4A and 4B).   Accordingly, 
an increase in the absorption of phenol red was suggested by continuous microinstillation. 
 Table 1 summarizes the recovery ratio in the peritoneal cavity, and biliary and urinary 
excretion ratios of phenol red at 4 h after instillation on the liver or small intestinal serosal 
surface under different instillation conditions.   Since the absorption from the peritoneal 
cavity was almost completed in 4 h, the recovery ratios of phenol red from the peritoneal 
cavity were less than 3 % of the dose.   The total biliary excretion ratio after 4 h of phenol 
red bolus instillation was higher than that after continuous microinstillation, while the urinary 
excretion ratio after continuous microinstillation was higher, although the difference was not 
significant.   The difference in the biliary and urinary excretion ratios of phenol red might 
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be considered to be alterations in the absorption route after continuous microinstillation and 
bolus instillation. 
Pharmacokinetic analysis of the plasma concentration profiles of phenol red 
AUC of the plasma concentration profile of phenol red (AUCp) was calculated until 10, 15, 30, 
60 and 240 min to examine time course of the absorption rate of phenol red, as shown in 
Table 2.   Continuous microinstillation on the liver and small intestinal serosal surface 
exhibited higher AUCp values of phenol red until 60 min after instillation compared with 
those after bolus instillation at either concentration, even though no difference was observed 
in AUC  values until 240 minp .   This indicates increased absorption from the liver and small 
intestinal serosal surface by continuous microinstillation.   In addition, the trend was marked 
in continuous microinstillation on the liver, compared to small intestinal serosal surface.
 Moreover, the plasma concentration profiles of phenol red were analyzed based on a 
compartment model as illustrated in Figures 2A and 2B, assuming that the absorption process 
after continuous microinstillation and bolus instillation follows first-order kinetics.   In case 
of continuous microinstillation, the plasma concentration profile during drug instillation (t < 
t0) was simulated based on Model A (Figure 2A) using the Ka value obtained with the model 
fitting of the plasma concentration profile after drug instillation (t > t0) based on the 
pharmacokinetic model shown in Figure 2B.   Figures 3 and 4 show the fitting curves under 
different instillation conditions.   In general, they agreed well with the experimental values 
and, therefore, the validity of this compartment model analysis was confirmed.   The 
deviation between the experimental and fitted values was observed in some data series 
(figures 3 and 4), due to the curve fitting procedure (nonlinear least square regression).
 The Ka values of phenol red under different conditions are listed in Table 2.   In the 
comparison of identical instillation sites, the Ka values of phenol red after continuous 
microinstillation were larger than those after bolus instillation, supporting the improvement of 
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absorbability by continuous microinstillation.   In addition, the Ka of phenol red was 
increased by 1.4 to 2.6-fold by reducing the instillation volume from 235 to 117.5 µL as 
shown in Table 2.   This finding is consistent with our observation that the Ka of phenol red 
after ip administration to the rat liver surface increased with decreasing application volume 
(Nishida et al 1997). 
Influence of the instillation site on the absorption rate of phenol red 
The pharmacokinetic analysis suggested that continuous microinstillation of phenol red 
resulted in faster absorption from the peritoneal cavity.   This tendency was significant after 
continuous microinstillation of 2.35 mg in 117.5 µL for 2.5 min on the liver surface, when it 
was about 3-fold higher Ka compared with bolus instillation (Table 2).   On the other hand, 
when comparing Ka at identical instillation volumes, the instillation of phenol red on the liver 
surface increased Ka by 1.2 to 2.3-fold compared with instillation on the small intestinal 
serosal surface.   We previously reported that the absorption rate from the peritoneal cavity 
was faster after ip administration on the liver surface than that after ip administration on the 
distal small intestinal serosal surface, as shown by the increase in the maximum concentration 
and the decrease in the mean residence time of phenol red in plasma (Nishida et al 1995b). 
 When drugs are instilled continuously, it appears that the drug concentration at the 
instillation site can be maintained because of the restricted distribution compared with bolus 
instillation.   In a previous study, the concentration of phenol red at the instillation site in the 
liver (left lateral lobe) was significantly higher than that at the other lobes of the liver after 
continuous microinstillation (Nakamura et al 1999).   However, when the same volume of 
drug solution was instilled on the small intestine or injected intravenously, no significant 
difference in drug concentration between the left lateral and other lobes was found, suggesting 
a uniform distribution of phenol red in the liver (Nakamura et al 1999). 
 
 In conclusion, a good absorption of phenol red from the instilled site of the liver was 
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attained by continuous microinstillation, possibly leading to restricted drug distribution in the 
liver.   Further information should be clarified for clinical relevance in the future. 
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Figure 1   Experimental method for drug instillation on the liver surface (left lobe) or small 
intestinal serosal surface in rats. 
Figure 2   Pharmacokinetic model for phenol red after continuous microinstillation or 
bolus instillation.   (Model A) t < t0, continuous microinstillation during drug instillation  
(Model B) t > t0, continuous microinstillation or bolus instillation 
 Xip, Amount in intraperitoneal compartment; C1, Concentration of central compartment; 
C2, Concentration of peripheral compartment; K0, Instillation rate; Ka, First-order absorption 
rate constant; Kel, First-order elimination rate constant; K12, K21, First-order transfer rate 
constant; Vc, Volume of central compartment; Vp, Volume of peripheral compartment 
Figure 3   Plasma concentration profiles of phenol red after continuous microinstillation 
for 5 min at a flow rate of 0.047 mL min-1 (closed circle) or bolus instillation (open circle) of 
2.35 mg in 235 µL on the liver or small intestinal serosal surface in rats.   Curves show the 
simulated function based on the pharmacokinetic parameters listed in Table 2.   Each point 
represents the mean ± s.e. of at least four experiments.   Significantly different from the 
result after bolus instillation (*P < 0.05, **P < 0.01). 
Figure 4   Plasma concentration profiles of phenol red after continuous microinstillation 
for 2.5 min at a flow rate of 0.047 mL min-1 (closed circle) or bolus instillation (open circle) 
of 2.35 mg in 117.5 µL on the liver or small intestinal serosal surface in rats.   Curves show 
the simulated function based on the pharmacokinetic parameters listed in Table 2.   Each 
point represents the mean ± s.e. of at least four experiments.   Significantly different from 





Table 1  Recovery (% of dose) after 4 h of phenol red continuous microinstillation or bolus 
instillation on the liver or small intestinal serosal surface in rats. 
 
 
Site Method Peritoneal         Bile                  Urine        
 cavity Free Metabolite Total  Free Metabolite Total 
 
 
2 .35 mg in 235 µL
Liver Continuous 1.9 25.2 13.8 39.0 30.8 9.0 39.8 
(5 min) ± 0.6 ± 4.7 ± 1.4 ± 5.6 ± 4.3 ± 1.7 ± 5.8  
 
 Bolus 1.7 33.6 10.1 43.7 20.7 4.8 25.5 
  ± 0.3 ± 2.3 ± 2.9 ± 4.5 ± 3.7 ± 1.3 ± 3.1 
 
Small Continuous 1.4 26.4 16.6 43.0 34.2 5.7 39.9 
ntestine (5 min) ± 0.5 ± 4.9 ± 2.4 ± 7.2 ± 5.7 ± 1.2 ± 5.5 i
 
 Bolus 2.7 32.5 16.0 48.5 20.3 6.1 26.4 
 
 
 ± 0.8 ± 5.3 ± 3.2 ± 7.9 ± 3.0 ± 1.8 ± 4.5 
 
2 .35 mg in 117.5 µL
Liver Continuous 1.4 24.4 12.0 36.4 35.4 5.2 40.6 
 (2.5 min) ± 0.6 ± 5.0 ± 3.0 ± 6.9 ± 4.6 ± 0.7 ± 4.7 
 
 Bolus 2.0 35.8 12.1 47.9 24.9 4.5 29.4 
 
 
 ± 0.2 ± 4.4 ± 3.1 ± 4.1 ± 2.0 ± 0.9 ± 1.7 
Small Continuous 1.5 32.6 15.2 47.8 37.8 4.3 42.1 
intestine (2.5 min) ± 0.3 ± 3.7 ± 2.2 ± 4.6 ± 3.2 ± 1.2 ± 3.8 
 
 Bolus 2.2 35.6 16.0 51.6 28.0 6.1 34.1 
 
 








Table 2  AUCp and Ka of phenol red after continuous microinstillation or bolus 
instillation on the liver or small intestinal serosal surface in rats. 
 
 
Site Method                AUCp (µg mL-1 min)           Ka





.35 mg in 235 µL 
Liver Continuous 103.5* 204.6** 502.8** 978.4* 1920.9 7.41** 
 (5 min) ± 4.5 ± 8.9 ± 23.9 ± 45.5 ± 135.7 ± 0.45 
 
 Bolus 80.8 142.7 344.8 728.2 1714.7 4.00 
 
 
 ± 9.4 ± 15.7 ± 34.1 ± 69.2 ± 215.3 ± 0.60 
Small Continuous 64.6 138.7 387.8* 880.8* 2038.7 3.93 
intestine (5 min) ± 4.6 ± 10.1 ± 23.6 ± 44.1 ± 146.8 ± 0.48 
 
 Bolus 58.3 111.2 294.8 651.4 1573.3 3.24 
 
 




.35 mg in 117.5 µL
Liver Continuous 152.7** 257.6** 521.6** 870.0 1436.0 19.35*** 
 (2.5 min) ± 4.8 ± 6.5 ± 13.7 ± 43.0 ± 145.8 ± 2.35 
 
 Bolus 103.0 175.2 387.6 751.4 1669.0 6.28 
 
 
 ± 2.2 ± 4.2 ± 12.3 ± 30.4 ± 78.8 ± 0.59 
Small Continuous 109.7 210.6 510.4 971.0 1766.4 8.38* 
intestine (2.5 min) ± 11.2 ± 21.5 ± 51.3 ± 91.2 ± 156.0 ± 1.10 
 
 Bolus 88.9 165.5 415.8 860.3 1909.2 4.44 
  ± 8.0 ± 13.6 ± 26.0 ± 47.1 ± 110.6 ± 0.44 
 
 
Each value is the mean ± s.e. of at least four experiments. 
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